Reuters Pharma USA 2024: What are key pharma players hoping to achieve?

By Isabel Cameron

- Last updated on GMT

© Getty Images
© Getty Images

Related tags Pharma Pharmaceutical industry

This week, the pharma industry will descend on Pennsylvania Convention Center for Reuters Pharma USA, North America’s largest cross-functional pharma gathering.

The event, running from March 26 to 27, will welcome a breadth of industry attendees, across commercial, marketing, medical affairs, RWE, market access, patient engagement, and key stakeholders.

Bio Pharma Reporter caught up with several key players to find out what they are planning to showcase ​and their key objectives.

SpringWorks Therapeutics

Spokesperson: Bhavesh Ashar, chief commercial officer at SpringWorks Therapeutics

What are your plans for Pharma USA?

At SpringWorks, we are re driven by our patient-focused values. During the panel I am participating in, I look forward to engaging with other like-minded peers to discuss how we can apply this mindset to develop the next wave of treatment advances and push ourselves to help underserved patient populations. I will also share key insights from our recent FDA approval and launch of the first and only FDA-approved treatment for adults with desmoid tumors and how we successfully delivered our therapy to patients within just days of the FDA approval.

What do you hope to achieve from the event?

This event is a great opportunity to exchange meaningful insights with other leaders in our industry who have successfully navigated barriers and brought important medicines to patient communities with high unmet needs. It is critical for us to engage in this dialogue, adapt, and apply learnings across the industry as we look to improve outcomes and shape a better future for the patients and families who are counting on our companies. 


Spokesperson: Mark Morgan, president and head of U.S. operations. 

What are your plans for Pharma USA?​ 

I’ll be attending sessions, and also will be presenting on March 26 at 2p.m. about our dynamic access environment and how UCB has uniquely addressed market access challenges with a robust framework. This includes how we are leveraging real-world data and evidence of the experiences of people living with severe diseases and feedback from our partners.

For example, we have worked with our partner Aetion, who is a leader in real-world analytics, to decrease our time to respond to payer queries, ultimately allowing us to demonstrate patient value faster. I will also discuss how we recognize the need to collaborate with health economics and outcomes (HEOR) teams, which has helped us understand the full patient experience in accessing their medicines. Finally, I will also touch on how we are working to understand how current and potential policies may impact value and access; we have even convened a coalition to help impact policies for one of the disease states UCB focuses on, hidradenitis suppurativa.

What do you hope to achieve from the event?​ 

I’m looking forward to conversations among attendees who are passionate about ensuring access and understanding how partnerships, data and policy all play a role in our work — and how we keep patients at the center of our decision making in these dynamic environments. It’s a challenge, and I look forward to sharing and learning.  

Nestlé Health Science

Spokesperson: Moreno Perugini, president of active and medical nutrition, U.S. & president of global pharmaceutical therapies. 

What are your plans for Reuters Pharma USA?

At Nestlé Health Science, we believe that every decision should be driven by the question, "What is the impact on patients?" This patient-centric mindset will be at the forefront as I participate in a panel discussion at Reuters Pharma USA. During the panel discussion, titled “Pharma's superpower: Leverage internal and external modern partnerships to drive a patient-first pharma culture”, I will emphasize the significance of collaboration and innovative partnerships in creating a healthcare ecosystem that truly makes a difference. 

What do you hope to achieve from the event?

I am genuinely excited to share Nestlé Health Science’s vision, some of our recent successes, and learn from the experiences and perspectives of other industry leaders at the event. Together we can deliver exceptional outcomes for patients while contributing to the betterment of the industry as a whole. 


What are your plans for Pharma USA?

Reuter Pharma USA event is set to be a busy one this year, with experts from across Inizio’s ecosystem attending to connect with faces old and new. Our team looks forward to welcoming attendees to our booth and our informative talks and workshops.

Experts from across Inizio Engage will be in attendance throughout, with Sese Abhulimen, President of Decision Optimization, and Mike Stout, President, US Commercial, presenting a session on “Impact driven commercialization: A data & evidence-driven approach.” The presentation on Tuesday, March 26 (2:20-2:40 pm) will look at using data as a connecting currency linking medical affairs goals with the needs of patients, physicians and payers. Our experts will show how data can optimise selling, general and administrative expenses (SG&A) as well as brand commercialisation, leading to more effective strategies.

What do you hope to achieve from the event?

The Inizio Engage Decision Optimization, US Commercial and Nazaré teams are excited to attend Reuters Pharma USA and let the industry know about Inizio Engage’s Next-Generation Commercial solutions.

Bob Dufour, Executive Consultant, Learning Solutions, and Susan Jordan, Performance Director, Nazaré, supported by Mike Stout and Hokan Ojert, SVP of Growth, US, will facilitate an interactive workshop titled “Mind the gap! Building a customer engagement workforce for tomorrow, utilising science, creativity and technology” for event attendees on Wednesday, March 27 (10:30-11:30 am). The workshop will analyse the customer experience landscape, allowing participants to discuss capability gaps and generate solutions utilising Nazaré’s framework. The learnings are based on our experts’ discussions with a range of pharmaceutical companies to understand the current and future engagement challenges and potential solutions. This session will give participants a clear understanding of what’s needed to identify capability gaps within sales and medical affairs teams and improve the skill and capability of teams to exceed set business objectives.

Inizio looks forward to this year’s Reuters Pharma USA as the opportunity to meet experts from across the industry and discover how our diverse range of capabilities can help navigate each pivotal moment of a customer’s clinical development and commercialisation journey.

Spokesperson: Nicole Huber, senior director, life sciences marketing.

What are your plans for Pharma USA? is attending Reuter’s Pharma USA and Nina Binetti, VP of Marketing at is on a panel session with other pharma leaders: “Unite behind a shared vision – define our AI future”. The session includes leaders from Genentech, Eisai and Genmab to identify trusted scientific and operational uses for AI’s, address use barriers and define outcome success metrics to increase internal appetite for utilization.

What do you hope to achieve from the event?

We look forward to connecting with other leaders in the industry and discussing how new technologies and approaches can be used to evolve commercial strategies, elevate HCP and patient engagement and lead to better health outcomes.

Grand View Health / Still Rise Farm

Spokesperson: Dr. Monique Gary, CEO of Still Rise Farm and breast surgeon and medical director-oncology at Grand View.

What are your plans for Pharma USA?

As a panellist for the discussion titled “Representation Matters: Championing Diversity from Bench to Bedside,” I’m enthusiastic to speak on my passion in fostering greater diversity and equity in clinical trials. My discussion will focus on how the new wave of technologies like AI can both help and harm us in healthcare, how we can partner with patients to tackle clinical trial participation challenges through education and trust-building efforts, and the importance of forging partnerships with policymakers and pharmaceutical leaders to establish an inclusive drug development framework that drives meaningful change. 

What do you hope to achieve from the event?

My hope is to foster meaningful industry discussions and explore potential solutions to pressing issues, especially the advancement of diversity and equity in clinical trials and beyond. My ultimate goal is to inspire actionable change and drive progress toward more representative and accessible healthcare for communities who are often overlooked and underserved.

Related news